Acute Myeloid Leukemia Market Size, Trends, Analysis, and Outlook By Disease (Myeloblastic, Promyelocytic, Myelomonocytic), By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Others), By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy, Others), By Regimen (DC Regimen, AVD Regimen, VCD Regimen), By End-User (Hospital, Retails Drug Stores, Ambulatory Care Centers, Clinics), by Country, Segment, and Companies, 2024-2032
The global Acute Myeloid Leukemia market size is poised to register 9.2% growth from 2024 to 2032, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Acute Myeloid Leukemia market across By Disease (Myeloblastic, Promyelocytic, Myelomonocytic), By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Others), By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy, Others), By Regimen (DC Regimen, AVD Regimen, VCD Regimen), By End-User (Hospital, Retails Drug Stores, Ambulatory Care Centers, Clinics)
With the increasing recognition of AML heterogeneity and the development of targeted therapies and immunotherapies, there is a rising need for personalized treatment approaches to improve outcomes in patients with AML across different age groups and risk categories. Market growth is driven by factors such as expanding research on leukemia biology and genetic mutations, the rising incidence of AML in older adults and secondary to myelodysplastic syndromes, and technological advancements in genomic profiling and targeted drug delivery systems. Additionally, the expanding applications of novel therapeutics in frontline and relapsed/refractory AML, as well as the growing adoption of allogeneic stem cell transplantation and maintenance therapy, contribute to market expansion. Further, the development of selective kinase inhibitors and monoclonal antibodies, the integration of immunotherapies and adoptive cell therapies into treatment algorithms, and the emphasis on early diagnosis and multidisciplinary care are expected to further accelerate market growth in the coming years.
Acute Myeloid Leukemia Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Acute Myeloid Leukemia market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Acute Myeloid Leukemia survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Acute Myeloid Leukemia industry.
Key market trends defining the global Acute Myeloid Leukemia demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Acute Myeloid Leukemia Market Segmentation- Industry Share, Market Size, and Outlook to 2032
The Acute Myeloid Leukemia industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Acute Myeloid Leukemia companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Acute Myeloid Leukemia industry
Leading Acute Myeloid Leukemia companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Acute Myeloid Leukemia companies.
Acute Myeloid Leukemia Market Study- Strategic Analysis Review
The Acute Myeloid Leukemia market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
The Acute Myeloid Leukemia industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.
Acute Myeloid Leukemia Country Analysis and Revenue Outlook to 2032
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2032.
North America Acute Myeloid Leukemia Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to $4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various Acute Myeloid Leukemia market segments. Similarly, Strong market demand is encouraging Canadian Acute Myeloid Leukemia companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico Acute Myeloid Leukemia market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Acute Myeloid Leukemia Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Acute Myeloid Leukemia industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European Acute Myeloid Leukemia market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Acute Myeloid Leukemia Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Acute Myeloid Leukemia in Asia Pacific. In particular, China, India, and South East Asian Acute Myeloid Leukemia markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.
Latin America Acute Myeloid Leukemia Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Acute Myeloid Leukemia Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Acute Myeloid Leukemia market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Acute Myeloid Leukemia.
Acute Myeloid Leukemia Market Company Profiles
The global Acute Myeloid Leukemia market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas Pharma Inc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Genmab A/S, Novartis AG, Oncolyze Inc, Otsuka Holdings Co. Ltd, Pfizer Inc, Sanofi SA, Sunesis Pharmaceuticals Inc, Syndax Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd.
Recent Acute Myeloid Leukemia Market Developments
The global Acute Myeloid Leukemia market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Acute Myeloid Leukemia Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
By Disease
Myeloblastic
Promyelocytic
Myelomonocytic
By Treatment
Chemotherapy
Targeted Therapy
Immunotherapy
Hormone Therapy
Others
By Chemotherapy
Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-metabolites
Tyrosine Kinase Inhibitors
Hormonal Therapy
Others
By Regimen
DC Regimen
AVD Regimen
VCD Regimen
By End-User
Hospital
Retails Drug Stores
Ambulatory Care Centers
Clinics
Geographical Segmentation:
AbbVie Inc
Agios Pharmaceuticals Inc
Amgen Inc
Astellas Pharma Inc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
Genmab A/S
Novartis AG
Oncolyze Inc
Otsuka Holdings Co. Ltd
Pfizer Inc
Sanofi SA
Sunesis Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Teva Pharmaceutical Industries Ltd
Formats Available: Excel, PDF, and PPT
With the increasing recognition of AML heterogeneity and the development of targeted therapies and immunotherapies, there is a rising need for personalized treatment approaches to improve outcomes in patients with AML across different age groups and risk categories. Market growth is driven by factors such as expanding research on leukemia biology and genetic mutations, the rising incidence of AML in older adults and secondary to myelodysplastic syndromes, and technological advancements in genomic profiling and targeted drug delivery systems. Additionally, the expanding applications of novel therapeutics in frontline and relapsed/refractory AML, as well as the growing adoption of allogeneic stem cell transplantation and maintenance therapy, contribute to market expansion. Further, the development of selective kinase inhibitors and monoclonal antibodies, the integration of immunotherapies and adoptive cell therapies into treatment algorithms, and the emphasis on early diagnosis and multidisciplinary care are expected to further accelerate market growth in the coming years.
Acute Myeloid Leukemia Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Acute Myeloid Leukemia market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Acute Myeloid Leukemia survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Acute Myeloid Leukemia industry.
Key market trends defining the global Acute Myeloid Leukemia demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Acute Myeloid Leukemia Market Segmentation- Industry Share, Market Size, and Outlook to 2032
The Acute Myeloid Leukemia industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Acute Myeloid Leukemia companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Acute Myeloid Leukemia industry
Leading Acute Myeloid Leukemia companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Acute Myeloid Leukemia companies.
Acute Myeloid Leukemia Market Study- Strategic Analysis Review
The Acute Myeloid Leukemia market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
- Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
- Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
- Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
- Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
The Acute Myeloid Leukemia industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.
Acute Myeloid Leukemia Country Analysis and Revenue Outlook to 2032
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2032.
North America Acute Myeloid Leukemia Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to $4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various Acute Myeloid Leukemia market segments. Similarly, Strong market demand is encouraging Canadian Acute Myeloid Leukemia companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico Acute Myeloid Leukemia market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Acute Myeloid Leukemia Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Acute Myeloid Leukemia industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European Acute Myeloid Leukemia market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Acute Myeloid Leukemia Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Acute Myeloid Leukemia in Asia Pacific. In particular, China, India, and South East Asian Acute Myeloid Leukemia markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.
Latin America Acute Myeloid Leukemia Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Acute Myeloid Leukemia Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Acute Myeloid Leukemia market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Acute Myeloid Leukemia.
Acute Myeloid Leukemia Market Company Profiles
The global Acute Myeloid Leukemia market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas Pharma Inc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Genmab A/S, Novartis AG, Oncolyze Inc, Otsuka Holdings Co. Ltd, Pfizer Inc, Sanofi SA, Sunesis Pharmaceuticals Inc, Syndax Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd.
Recent Acute Myeloid Leukemia Market Developments
The global Acute Myeloid Leukemia market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Acute Myeloid Leukemia Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
- Pricing Analysis
- Value Chain Analysis
- SWOT Profile
- Market Dynamics- Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- Macroeconomic Impact Analysis
- Case Scenarios- Low, Base, High
By Disease
Myeloblastic
Promyelocytic
Myelomonocytic
By Treatment
Chemotherapy
Targeted Therapy
Immunotherapy
Hormone Therapy
Others
By Chemotherapy
Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-metabolites
Tyrosine Kinase Inhibitors
Hormonal Therapy
Others
By Regimen
DC Regimen
AVD Regimen
VCD Regimen
By End-User
Hospital
Retails Drug Stores
Ambulatory Care Centers
Clinics
Geographical Segmentation:
- North America (3 markets)
- Europe (6 markets)
- Asia Pacific (6 markets)
- Latin America (3 markets)
- Middle East Africa (5 markets)
AbbVie Inc
Agios Pharmaceuticals Inc
Amgen Inc
Astellas Pharma Inc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
Genmab A/S
Novartis AG
Oncolyze Inc
Otsuka Holdings Co. Ltd
Pfizer Inc
Sanofi SA
Sunesis Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Teva Pharmaceutical Industries Ltd
Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY
1.1 Acute Myeloid Leukemia Market Overview and Key Findings, 2024
1.2 Acute Myeloid Leukemia Market Size and Growth Outlook, 2021- 2030
1.3 Acute Myeloid Leukemia Market Growth Opportunities to 2030
1.4 Key Acute Myeloid Leukemia Market Trends and Challenges
1.4.1 Acute Myeloid Leukemia Market Drivers and Trends
1.4.2 Acute Myeloid Leukemia Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Acute Myeloid Leukemia Companies
2. ACUTE MYELOID LEUKEMIA MARKET SIZE OUTLOOK TO 2030
2.1 Acute Myeloid Leukemia Market Size Outlook, USD Million, 2021- 2030
2.2 Acute Myeloid Leukemia Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. ACUTE MYELOID LEUKEMIA MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. ACUTE MYELOID LEUKEMIA MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Disease
Myeloblastic
Promyelocytic
Myelomonocytic
By Treatment
Chemotherapy
Targeted Therapy
Immunotherapy
Hormone Therapy
Others
By Chemotherapy
Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-metabolites
Tyrosine Kinase Inhibitors
Hormonal Therapy
Others
By Regimen
DC Regimen
AVD Regimen
VCD Regimen
By End-User
Hospital
Retails Drug Stores
Ambulatory Care Centers
Clinics
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Acute Myeloid Leukemia Market, 2025
5.2 Asia Pacific Acute Myeloid Leukemia Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Acute Myeloid Leukemia Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Acute Myeloid Leukemia Market, 2025
5.5 Europe Acute Myeloid Leukemia Market Size Outlook by Type, 2021- 2030
5.6 Europe Acute Myeloid Leukemia Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Acute Myeloid Leukemia Market, 2025
5.8 North America Acute Myeloid Leukemia Market Size Outlook by Type, 2021- 2030
5.9 North America Acute Myeloid Leukemia Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Acute Myeloid Leukemia Market, 2025
5.11 South America Pacific Acute Myeloid Leukemia Market Size Outlook by Type, 2021- 2030
5.12 South America Acute Myeloid Leukemia Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Acute Myeloid Leukemia Market, 2025
5.14 Middle East Africa Acute Myeloid Leukemia Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Acute Myeloid Leukemia Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Acute Myeloid Leukemia Market Size Outlook and Revenue Growth Forecasts
6.2 US Acute Myeloid Leukemia Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Acute Myeloid Leukemia Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Acute Myeloid Leukemia Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Acute Myeloid Leukemia Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Acute Myeloid Leukemia Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Acute Myeloid Leukemia Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Acute Myeloid Leukemia Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Acute Myeloid Leukemia Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Acute Myeloid Leukemia Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Acute Myeloid Leukemia Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Acute Myeloid Leukemia Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Acute Myeloid Leukemia Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Acute Myeloid Leukemia Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Acute Myeloid Leukemia Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Acute Myeloid Leukemia Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Acute Myeloid Leukemia Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Acute Myeloid Leukemia Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Acute Myeloid Leukemia Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Acute Myeloid Leukemia Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Acute Myeloid Leukemia Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Acute Myeloid Leukemia Industry Drivers and Opportunities
7. ACUTE MYELOID LEUKEMIA MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. ACUTE MYELOID LEUKEMIA COMPANY PROFILES
8.1 Profiles of Leading Acute Myeloid Leukemia Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
AbbVie Inc
Agios Pharmaceuticals Inc
Amgen Inc
Astellas Pharma Inc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
Genmab A/S
Novartis AG
Oncolyze Inc
Otsuka Holdings Co. Ltd
Pfizer Inc
Sanofi SA
Sunesis Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Teva Pharmaceutical Industries Ltd.
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
1.1 Acute Myeloid Leukemia Market Overview and Key Findings, 2024
1.2 Acute Myeloid Leukemia Market Size and Growth Outlook, 2021- 2030
1.3 Acute Myeloid Leukemia Market Growth Opportunities to 2030
1.4 Key Acute Myeloid Leukemia Market Trends and Challenges
1.4.1 Acute Myeloid Leukemia Market Drivers and Trends
1.4.2 Acute Myeloid Leukemia Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Acute Myeloid Leukemia Companies
2. ACUTE MYELOID LEUKEMIA MARKET SIZE OUTLOOK TO 2030
2.1 Acute Myeloid Leukemia Market Size Outlook, USD Million, 2021- 2030
2.2 Acute Myeloid Leukemia Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. ACUTE MYELOID LEUKEMIA MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. ACUTE MYELOID LEUKEMIA MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Disease
Myeloblastic
Promyelocytic
Myelomonocytic
By Treatment
Chemotherapy
Targeted Therapy
Immunotherapy
Hormone Therapy
Others
By Chemotherapy
Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-metabolites
Tyrosine Kinase Inhibitors
Hormonal Therapy
Others
By Regimen
DC Regimen
AVD Regimen
VCD Regimen
By End-User
Hospital
Retails Drug Stores
Ambulatory Care Centers
Clinics
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Acute Myeloid Leukemia Market, 2025
5.2 Asia Pacific Acute Myeloid Leukemia Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Acute Myeloid Leukemia Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Acute Myeloid Leukemia Market, 2025
5.5 Europe Acute Myeloid Leukemia Market Size Outlook by Type, 2021- 2030
5.6 Europe Acute Myeloid Leukemia Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Acute Myeloid Leukemia Market, 2025
5.8 North America Acute Myeloid Leukemia Market Size Outlook by Type, 2021- 2030
5.9 North America Acute Myeloid Leukemia Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Acute Myeloid Leukemia Market, 2025
5.11 South America Pacific Acute Myeloid Leukemia Market Size Outlook by Type, 2021- 2030
5.12 South America Acute Myeloid Leukemia Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Acute Myeloid Leukemia Market, 2025
5.14 Middle East Africa Acute Myeloid Leukemia Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Acute Myeloid Leukemia Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Acute Myeloid Leukemia Market Size Outlook and Revenue Growth Forecasts
6.2 US Acute Myeloid Leukemia Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Acute Myeloid Leukemia Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Acute Myeloid Leukemia Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Acute Myeloid Leukemia Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Acute Myeloid Leukemia Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Acute Myeloid Leukemia Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Acute Myeloid Leukemia Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Acute Myeloid Leukemia Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Acute Myeloid Leukemia Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Acute Myeloid Leukemia Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Acute Myeloid Leukemia Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Acute Myeloid Leukemia Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Acute Myeloid Leukemia Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Acute Myeloid Leukemia Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Acute Myeloid Leukemia Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Acute Myeloid Leukemia Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Acute Myeloid Leukemia Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Acute Myeloid Leukemia Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Acute Myeloid Leukemia Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Acute Myeloid Leukemia Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Acute Myeloid Leukemia Industry Drivers and Opportunities
7. ACUTE MYELOID LEUKEMIA MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. ACUTE MYELOID LEUKEMIA COMPANY PROFILES
8.1 Profiles of Leading Acute Myeloid Leukemia Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
AbbVie Inc
Agios Pharmaceuticals Inc
Amgen Inc
Astellas Pharma Inc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
Genmab A/S
Novartis AG
Oncolyze Inc
Otsuka Holdings Co. Ltd
Pfizer Inc
Sanofi SA
Sunesis Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Teva Pharmaceutical Industries Ltd.
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
